Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., Samant, T. S., Longmire, T., Chowdhury, N. R., Sabatos-Peyton, C. A., Patel, N., Ramesh, R., Hu, T., Carion, A., Gusenleitner, D., Yerramilli-Rao, P., Askoxylakis, V., Kwak, E. L., & Hong, D. S. (2022). phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for immunotherapy of cancer, 10(2), . http://access.bl.uk/ark:/81055/vdc_100151273983.0x000006